Independent influence of overweight and obesity on the regression of left ventricular hypertrophy in hypertensive patients: A meta-analysis

Medicine (United States)

Volumn 93, Issue 25, 2014, Pages

  Zhang, Kun ^a,b   Huang, Feifei ^a,b   Chen, Jie ^b,c   Cai, Qingqing ^a   Wang, Tong ^b   Zou, Rong ^b   Zuo, Zhiyi ^d   Wang, Jingfeng ^a,b   Huang, Hui ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology   (China)

^c SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIAC PATIENT; CONTROLLED STUDY; EVALUATION STUDY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); OBESITY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

EID: 84916613542     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000130     Document Type: Article

References (61)

1. Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA. 1999;282:1530-1538.
2. Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580-586.
3. Reisin E, Jack AV. Obesity and hypertension: mechanisms, cardiorenal consequences, and therapeutic approaches. Med Clin North Am. 2009;93:733-751.
4. Ballo P, Motto A, Mondillo S, et al. Impact of obesity on left ventricular mass and function in subjects with chronic volume overload. Obesity (Silver Spring). 2007;15:2019-2026.
5. Jhaveri RR, Pond KK, Hauser TH, et al. Cardiac remodeling after substantial weight loss: a prospective cardiac magnetic resonance study after bariatric surgery. Surg Obes Relat Dis. 2009;5:648-652.
6. Haufe S, Utz W, Engeli S, et al. Left ventricular mass and function with reduced-fat or reduced-carbohydrate hypocaloric diets in overweight and obese subjects. Hypertension. 2012;59:70-75.
7. Hsuan CF, Huang CK, Lin JW, et al. The effect of surgical weight reduction on left ventricular structure and function in severe obesity. Obesity (Silver Spring). 2010;18:1188-1193.
8. Barouch LA. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation. 2003;108:754-759.
9. Fagard RH, Celis H, Thijs L, et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084-1091.
10. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156-161.
11. Cuspidi C, Meani S, Sala C, et al. Age related prevalence of severe left ventricular hypertrophy in essential hypertension: echocardiographic findings from the ETODH study. Blood Press. 2012;21:139-145.
12. Zhang K, Chen J, Liu Y, et al. Diastolic blood pressure reduction contributes more to the regression of left ventricular hypertrophy: a meta-analysis of randomized controlled trials. J Hum Hypertens. 2013;27:698-706.
13. Dahlof B, Hansson L. Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide. J Hypertens. 1992;10:1513-1524.
14. Jula AM, Karanko HM. Effects on left ventricular hypertrophy of long-term nonpharmacological treatment with sodium restriction in mild-to-moderate essential hypertension. Circulation. 1994;89:1023-1031.
15. Diez J, Laviades C. Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril. J Hypertens Suppl. 1994;12:S31-S36.
16. Grandi AM, Bignotti M, Gaudio G, et al. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine. J Cardiovasc Pharmacol. 1995;26:737-741.
17. Schobel HP, Langenfeld M, Gatzka C, et al. Treatment and posttreatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension. Am Heart J. 1996;132:1004-1009.
18. Ueno H, Takata M, Tomita S, et al. The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors. J Cardiovasc Pharmacol. 1997;30:643-648.
19. Roman MJ, Alderman MH, Pickering TG, et al. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens. 1998;11:387-396.
20. Agabiti-Rosei E, Zulli R, Muiesan ML, et al. Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients. Blood Press. 1998;7:160-169.
21. Martina B, Dieterle T, Weinbacher M, et al. Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology. 1999;92:110-114.
22. Cheung BM, Lau CP. Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. Br J Clin Pharmacol. 1999;47:179-187.
23. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000;18:1465-1475.
24. Avanza AC Jr, El Aouar LM, Mill JG. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. Arq Bras Cardiol. 2000;74:103-117.
25. Novo S, Abrignani MG, Novo G, et al. Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. Am J Hypertens. 2001;14:637-643.
26. Skudicky D, Sareli P, Libhaber E, et al. Relationship between treatment-induced changes in left ventricular mass and blood pressure in black african hypertensive patients: results of the Baragwanath Trial. Circulation. 2002;105:830-836.
27. Cuspidi C, Muiesan ML, Valagussa L, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens. 2002;20:2293-2300.
28. Takami T, Shigematsu M. Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension. Clin Exp Hypertens. 2003;25:525-535.
29. Sakata K, Yoshida H, Tamekiyo H, et al. Comparative effect of clinidipine and quinapril on left ventricular mass in mild essential hypertension. Drugs Exp Clin Res. 2003;29:117-123.
30. Yasunari K, Maeda K, Watanabe T, et al. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol. 2004;43:2116-2123.
31. Rinder MR, Spina RJ, Peterson LR, et al. Comparison of effects of exercise and diuretic on left ventricular geometry, mass, and insulin resistance in older hypertensive adults. Am J Physiol Regul Integr Comp Physiol. 2004;287:R360-368.
32. de Luca N, Mallion JM, O'Rourke MF, et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens. 2004;17:660-667.
33. Bilge AK, Atilgan D, Tukek T, et al. Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mildto- moderate essential hypertension. Int J Clin Pract. 2005;59:306-310.
34. Anan F, Takahashi N, Ooie T, et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol. 2005;61:353-359.
35. Agabiti-Rosei E, Trimarco B, Muiesan ML, et al. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2005;23:1091-1098.
36. Grandi AM, Solbiati F, Laurita E, et al. Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Am J Hypertens. 2008;21:231-237.
37. Takami T, Saito Y. Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study. Vasc Health Risk Manag. 2011;7:383-390.
38. Pan XD, Zeng ZH, Liang LY, et al. The effects of simvastatin on left ventricular hypertrophy and left ventricular function in patients with essential hypertension. Clin Exp Hypertens. 2011;33:558-564.
39. Caglar N, Dincer I. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial. Eur Rev Med Pharmacol Sci. 2011;15:1359-1368.
40. Fogari R, Mugellini A, Destro M, et al. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. Diabet Med. 2012;29:24-31.
41. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1-253.
42. Kannel WB, Brand N, Skinner JJ Jr et al. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med. 1967;67:48-59.
43. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-313.
44. Palmieri V, de Simone G, Arnett DK, et al. Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology Network Study). Am J Cardiol. 2001;88:1163-1168.
45. Pruette CS, Fivush BA, Flynn JT, et al. Effects of obesity and race on left ventricular geometry in hypertensive children. Pediatr Nephrol. 2013;28:2015-2022.
46. Barron AJ, Hughes AD, Sharp A, et al. Long-term antihypertensive treatment fails to improve E/e' despite regression of left ventricular mass: an Anglo-Scandinavian cardiac outcomes trial substudy. Hypertension. 2014;63:252-258.
47. Ku CS, Lin SL, Wang DJ, et al. Left ventricular filling in young normotensive obese adults. Am J Cardiol. 1994;73:613-615.
48. Sasson Z, Rasooly Y, Bhesania T, et al. Insulin resistance is an important determinant of left ventricular mass in the obese. Circulation. 1993;88:1431-1436.
49. Federici M, Guerra F, Mancinelli L, et al. The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients. PLoS One. 2011;6:e16630.
50. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med (Berl). 2001;79:21-29.
51. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289:1799-1804.
52. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
53. Jordan J, Yumuk V, Schlaich M, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012;30:1047-1055.
54. Yasue S, Ebihara K, Nakao K. [Adipose tissue renin-angiotensin system in obese]. Nihon Rinsho. 2012;70:1550-1555.
55. Ruster C, Wolf G. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin Nephrol. 2013;33: 44-53.
56. Sarzani R, Guerra F, Mancinelli L, et al. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment. Am J Hypertens. 2012;25:818-826.
57. Brook RD, Bard RL, Kehrer C, et al. Valsartan improves insulin sensitivity without altering vascular function in healthy overweight adults without the metabolic syndrome. Metab Syndr Relat Disord. 2007;5:255-261.
58. Marinik EL, Frisard MI, Hulver MW, et al. Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure. Ther Adv Cardiovasc Dis. 2013;7:11-20.
59. Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370:1219-1229.
60. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407-2415.
61. Wildman RP, Mackey RH, Bostom A, et al. Measures of obesity are associated with vascular stiffness in young and older adults. Hypertension. 2003;42:468-473.